Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer - A randomized trial from the South Sweden Breast Cancer Group.
(2009) In Breast 18. p.309-315- Abstract
- PURPOSE: To study long term loco-regional and distant recurrence rate and survival after post-mastectomy radiotherapy in combination with oral cyclophosphamide in premenopausal women with stage II breast cancer. STUDY DESIGN: A three-armed randomized multicenter phase III trial comparing 1) Radiotherapy (RT) 2) RT+ oral cyclophosphamide for one year (RT+C) and 3) Oral cyclophosphamide only (C). Radiotherapy was administered, in 20 fractions, to 48Gy to the axilla and parasternal lymph nodes, 45Gy to infra- and supraclavicular fossae and 38Gy to the chest wall. Cyclophosphamide was prescribed as 12 courses of 130mg/m(2) od for14 days every 4 weeks. PATIENTS AND METHODS: 367 patients from 15 surgical departments in Southern Sweden,... (More)
- PURPOSE: To study long term loco-regional and distant recurrence rate and survival after post-mastectomy radiotherapy in combination with oral cyclophosphamide in premenopausal women with stage II breast cancer. STUDY DESIGN: A three-armed randomized multicenter phase III trial comparing 1) Radiotherapy (RT) 2) RT+ oral cyclophosphamide for one year (RT+C) and 3) Oral cyclophosphamide only (C). Radiotherapy was administered, in 20 fractions, to 48Gy to the axilla and parasternal lymph nodes, 45Gy to infra- and supraclavicular fossae and 38Gy to the chest wall. Cyclophosphamide was prescribed as 12 courses of 130mg/m(2) od for14 days every 4 weeks. PATIENTS AND METHODS: 367 patients from 15 surgical departments in Southern Sweden, representing 80% of all eligible patients, were included in the trial between 1978-1983. Median age was 47 years, median tumour size was 25mm, and 33% of the patients were lymph node negative. Median follow-up time was 24 years. RESULTS: RT reduced the risk at twenty years for loco-regional recurrence in C-treated patients at twenty years with 75% (13.9% vs. 3.5%). The risk reduction was highly significant in both N0 and N+ patients. No reduction in systemic disease or mortality was observed. CONCLUSION: Post-mastectomy radiotherapy reduced loco-regional recurrences in this premenopausal population, but no effect was seen on mortality with 20 years follow-up. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1500502
- author
- Killander, Fredrika LU ; Anderson, Harald LU ; Rydén, Stefan ; Möller, Torgil LU ; Hafström, L O and Malmström, Per LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Breast
- volume
- 18
- pages
- 309 - 315
- publisher
- Churchill Livingstone
- external identifiers
-
- wos:000272274400010
- pmid:19811918
- scopus:71049194712
- ISSN
- 1532-3080
- DOI
- 10.1016/j.breast.2009.09.006
- language
- English
- LU publication?
- yes
- id
- dd5c95b5-7efe-4ba6-8a29-1dff26a7ef05 (old id 1500502)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19811918?dopt=Abstract
- date added to LUP
- 2016-04-04 09:18:46
- date last changed
- 2022-04-23 19:57:10
@article{dd5c95b5-7efe-4ba6-8a29-1dff26a7ef05,
abstract = {{PURPOSE: To study long term loco-regional and distant recurrence rate and survival after post-mastectomy radiotherapy in combination with oral cyclophosphamide in premenopausal women with stage II breast cancer. STUDY DESIGN: A three-armed randomized multicenter phase III trial comparing 1) Radiotherapy (RT) 2) RT+ oral cyclophosphamide for one year (RT+C) and 3) Oral cyclophosphamide only (C). Radiotherapy was administered, in 20 fractions, to 48Gy to the axilla and parasternal lymph nodes, 45Gy to infra- and supraclavicular fossae and 38Gy to the chest wall. Cyclophosphamide was prescribed as 12 courses of 130mg/m(2) od for14 days every 4 weeks. PATIENTS AND METHODS: 367 patients from 15 surgical departments in Southern Sweden, representing 80% of all eligible patients, were included in the trial between 1978-1983. Median age was 47 years, median tumour size was 25mm, and 33% of the patients were lymph node negative. Median follow-up time was 24 years. RESULTS: RT reduced the risk at twenty years for loco-regional recurrence in C-treated patients at twenty years with 75% (13.9% vs. 3.5%). The risk reduction was highly significant in both N0 and N+ patients. No reduction in systemic disease or mortality was observed. CONCLUSION: Post-mastectomy radiotherapy reduced loco-regional recurrences in this premenopausal population, but no effect was seen on mortality with 20 years follow-up.}},
author = {{Killander, Fredrika and Anderson, Harald and Rydén, Stefan and Möller, Torgil and Hafström, L O and Malmström, Per}},
issn = {{1532-3080}},
language = {{eng}},
pages = {{309--315}},
publisher = {{Churchill Livingstone}},
series = {{Breast}},
title = {{Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer - A randomized trial from the South Sweden Breast Cancer Group.}},
url = {{http://dx.doi.org/10.1016/j.breast.2009.09.006}},
doi = {{10.1016/j.breast.2009.09.006}},
volume = {{18}},
year = {{2009}},
}